Biotech is not for the faint of heart. About 90% of drugs and therapies tested fail to make it to market. Even drugs with promising phase 2 data are up against huge odds of failure -- as Incyte (NASDAQ: INCY)shareholders were reminded of all too well today.
Why One Drug Flop Tanked Incyte's Stock
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться